VIPDOMET 12.5/1000; 12.5 mg alogliptin (as benzoate) / 1000 mg metformin hydrochloride film-coated tablets blister pack

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

metformin hydrochloride, Quantity: 1000 mg; alogliptin benzoate, Quantity: 17 mg (Equivalent: alogliptin, Qty 12.5 mg)

Available from:

Takeda Pharmaceuticals Australia Pty Ltd

INN (International Name):

Alogliptin benzoate,Metformin hydrochloride

Pharmaceutical form:

Tablet, film coated

Composition:

Excipient Ingredients: mannitol; purified talc; iron oxide yellow; povidone; microcrystalline cellulose; magnesium stearate; titanium dioxide; crospovidone; hypromellose

Administration route:

Oral

Units in package:

120, 112, 180, 56, 60, 14, 10, 196, 28, 98, 200, 20

Prescription type:

(S4) Prescription Only Medicine

Therapeutic indications:

VIPDOMET is indicated to improve glycaemic control in adult patients (> or = 18 years old) with type 2 diabetes mellitus when diet and exercise do not provide adequate glycaemic control and treatment with both alogliptin and metformin is appropriate,,- when treatment with metformin alone does not provide adequate control; or - in combination with a thiazolidinedione or with insulin, when dual therapy does not provide adequate control.,VIPDOMET can also be used to replace separate tablets of alogliptin and metformin in patients already being treated with this combination.

Product summary:

Visual Identification: Pale yellow, oblong, biconvex, film-coated tablets with 12.5/1000 debossed on one side and 322M debossed on the other side.; Container Type: Blister Pack; Container Material: PVC/PCTFE (Aclar)/Al; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius

Authorization status:

Registered

Authorization date:

2013-10-22